CN106692147A - Medicinal composition for treating male infertility - Google Patents
Medicinal composition for treating male infertility Download PDFInfo
- Publication number
- CN106692147A CN106692147A CN201710067451.0A CN201710067451A CN106692147A CN 106692147 A CN106692147 A CN 106692147A CN 201710067451 A CN201710067451 A CN 201710067451A CN 106692147 A CN106692147 A CN 106692147A
- Authority
- CN
- China
- Prior art keywords
- male sterility
- compound
- medicinal composition
- pharmaceutical composition
- treating male
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
Abstract
The invention relates to a medicinal composition for treating male infertility. The medicinal composition comprises a compound or pharmaceutically acceptable salt and a pharmaceutically acceptable carrier thereof as shown in the specification. The medicinal composition can be used for treating male infertility, and is expected to be developed into a novel clinical medicine.
Description
Technical field
The present invention relates to field of medicaments, specifically, the present invention relates to a kind of pharmaceutical composition for treating male sterility
Background technology
The infertile title male sterility in the wife's side is caused due to bridegroom's or husband's side reason, male sterility is a kind of refractory illness of comparing.
Data at home and abroad shows：15 pairs of patients with infertility are there is in every 100 couples of Mr. and Mrs.Chinese population radix is big, relative incidence probability
Height, also in rising trend in recent years, wherein reason is that the bridegroom's or husband's side accounts for 50%.Current China's pharmaceutical technology field is in treatment male
Sterility aspect have accumulated more rich experience, and such as using hormone drug, operation, local application, but effect is all not satisfactory.
Therefore, people wished to always it is a kind of it is evident in efficacy, having no side effect can improve semen quality, accelerate mankind spermatozoon and formed, carry
The medicine of the treatment male sterility of fecundity high.
The content of the invention
It is an object of the invention to provide a kind of pharmaceutical composition for treating male sterility.
In order to realize the purpose of the present invention, the present invention provides a kind of pharmaceutical composition for treating male sterility, the medicine
Compound of the composition comprising following formula or its pharmaceutically acceptable salt and pharmaceutically acceptable carrier：
Preferably, described pharmaceutical composition can be made tablet, dispersible tablet, disintegrated tablet or sustained release tablets.
The present invention also provides purposes of the compound in the medicine for preparing treatment male sterility, and the compound has following
Structure：
Medicine of the present invention can be used for treating male sterility and related symptoms, obstacle and disease, be expected to be developed into
New drug clinically.
Specific embodiment
It will be appreciated by those skilled in the art that the concept and specific embodiment disclosed in description above can be easy to
With making an amendment or design the basis of the other embodiment for implementing identical purpose of the invention.What those skilled in the art also will be understood that
It is that these equivalent implementation methods are without departing from the spirit and scope of the present invention illustrated in appended claims.
The sign of the compounds of this invention of experimental example 1
1H NMR(300MHz,MeOD)δ1.90-2.00(4H,m),2.10-2.20(2H,m),2.81-3.00(8H,m),
3.04-3.17(2H,m),3.28(3H,s),3.6(3H,s),3.85-3.96(1H,m),4.48(2H,t),5.00-5.13(1H,
m),6.88(1H,d),7.82(1H,d),8.05(1H,d),8.43-8.50(2H,m),8.83(1H,s)。
Therapeutic effect of the medicine of the present invention of experimental example 2 for male sterility
Cleaning grade ICR male mices 40 are taken, body weight (30 ± 5) g is randomly divided into 4 groups, every group 10.Normal group,
Model group, positive drug (testosterone propionate parenteral solution, specification 25mgmL-l) group, the compounds of this invention group.
Each group dosage is as follows：Normal group, model group give physiological saline gavage 1mL/1000g body weight；Positive drug
Group, hypodermic injection testosterone propionate parenteral solution, 5mgkg-1；Administration group 1；The compounds of this invention group, the compound of 0.03g adds
2000mL normal salines give gavage 1mL/1000g body weight into suspension.One time a day above.Except Normal group
Outward, each group is being administered the 6th day equal intraperitoneal injection hydrocortisone 25mgkg-1Carry out modeling.Then each group is according to side before
Formula continues to be administered 14 days.
24h puts to death mouse after last dose, and Prostate glands-seminal vesicle, testis, preputial gland separate the knot such as peripheral adipose
Form tissue.Testis and preputial gland are weighed immediately.Prostato- seminal vesicle, it is fixed in Bovin's liquid, overnight.After taking-up, reject
The connective tissue of attachment.Left side epididymis is separated, is shredded in the culture dish for filling the aseptic PBS liquid of 20mL, tissue is clamped with tweezers
Cyclic washing, makes sperm separate out, as 37 DEG C of incubation 30min, sperm suspension.
Sperm quantity is counted with blood cell counting plate method.Result see the table below.
Compare with Normal group, * P<0.05, show modeling success；Compare with model group,ΔP<0.05, illustrate positive drug
Thing and the compounds of this invention are respectively provided with drug effect, can significantly improve sperm quantity.
Claims (3)
1. a kind of pharmaceutical composition for treating male sterility, it is characterised in that compound of the described pharmaceutical composition comprising following formula
Or its pharmaceutically acceptable salt and pharmaceutically acceptable carrier, the compound has having structure：
2. it is according to claim 1 treatment male sterility pharmaceutical composition, it is characterised in that described pharmaceutical composition can
To be made tablet, dispersible tablet, disintegrated tablet or sustained release tablets.
3. compound prepare treatment male sterility medicine in purposes, it is characterised in that the compound has following knot
Structure：
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710067451.0A CN106692147A (en) | 2017-02-07 | 2017-02-07 | Medicinal composition for treating male infertility |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710067451.0A CN106692147A (en) | 2017-02-07 | 2017-02-07 | Medicinal composition for treating male infertility |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106692147A true CN106692147A (en) | 2017-05-24 |
Family
ID=58909924
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710067451.0A Pending CN106692147A (en) | 2017-02-07 | 2017-02-07 | Medicinal composition for treating male infertility |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106692147A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1939194A1 (en) * | 2005-09-07 | 2008-07-02 | Banyu Pharmaceutical Co., Ltd. | Bicyclic aromatic substituted pyridone derivative |
| CN105777730A (en) * | 2016-04-07 | 2016-07-20 | 陈思思 | Pharmaceutical composition for treating male infertility |
| CN106255692A (en) * | 2014-05-08 | 2016-12-21 | 阿斯利康(瑞典)有限公司 | Imidazo [4,5 c] quinoline 2 ketonic compound and their purposes in treatment cancer |
-
2017
- 2017-02-07 CN CN201710067451.0A patent/CN106692147A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1939194A1 (en) * | 2005-09-07 | 2008-07-02 | Banyu Pharmaceutical Co., Ltd. | Bicyclic aromatic substituted pyridone derivative |
| CN106255692A (en) * | 2014-05-08 | 2016-12-21 | 阿斯利康(瑞典)有限公司 | Imidazo [4,5 c] quinoline 2 ketonic compound and their purposes in treatment cancer |
| CN105777730A (en) * | 2016-04-07 | 2016-07-20 | 陈思思 | Pharmaceutical composition for treating male infertility |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2018086498A1 (en) | Pharmaceutical composition and application thereof | |
| RU2014142267A (en) | MEDICINE FOR TREATMENT OF ACUTE MYELOID LEukemia (AML) | |
| RU2013111954A (en) | METHOD OF TREATMENT FROM LATERAL AMYOTROPHIC SCLEROSIS | |
| RU2015134581A (en) | NITROXIL DONORS WITH IMPROVED THERAPEUTIC INDEX | |
| JP2010511596A5 (en) | ||
| EP3784650B1 (en) | N-phenyl-n'-(4-{[6-(1h-imidazol-1-yl)-4-pyrimidinyl]amino}phenyl)urea derivatives as mct4 inhibitors for the treatment of cancer | |
| CN111110824A (en) | Medicinal composition for strengthening body resistance and rescuing lung and application thereof | |
| RU2012128109A (en) | METHODS FOR CARRYING THERAPY OF WEIGHT LOSS IN PATIENTS WITH DOMINANT DEPRESSION (OPTIONS) | |
| JP2018531605A5 (en) | ||
| CN105726472B (en) | bendamustine medicament composition and application thereof | |
| WO2018223625A1 (en) | Pharmaceutical composition and use thereof | |
| CN106692147A (en) | Medicinal composition for treating male infertility | |
| CN109481487B (en) | Application of taraxasterone in preparation of medicine for preventing and treating senile dementia | |
| WO2020143332A1 (en) | Application of ilexgenin o in preparation of medication for preventing and treating alzheimer's disease | |
| CN112156088B (en) | Application of compound in preparation of mycobacterium tuberculosis inhibitor | |
| CN110833553A (en) | Use of pyrazolopyrimidine derivatives for the treatment of Arthus response | |
| CN112603998B (en) | A compound preparation containing troxerutin for treating thrombi and its preparation method | |
| CN110013474A (en) | The new application of fenofibrate and drug for new application | |
| CN1234369C (en) | Bacillus prodigiosus polysaccharide for nose drops | |
| RU2499594C1 (en) | Method of treating chronic endometritis | |
| RU2669399C1 (en) | Agent including cyclic glucose oligomer (options), its application and method of creating reversible pharmacologically induced hypometabolism and hypothermia | |
| CN1332669C (en) | Dripping pills for reducing swelling and easing pain and its preparing method | |
| WO2022007831A1 (en) | Medical use of composition | |
| CN116036102A (en) | Use of Manacastine to reduce intestinal damage caused by XELOX combination treatment regimen | |
| CN113893246A (en) | Application of procaterol hydrochloride in preparation of medicine for treating gastritis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170524 |
|
| RJ01 | Rejection of invention patent application after publication |